lopinavir-ritonavir

Global COVID-19 treatment trial shows current antivirals are of little benefit to hospitalized patients

Interim results from the Solidarity Therapeutics Trial indicate that remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon regimens appeared to have little or no effect on 28-day mortality or the in-hospital course of COVID-19 among hospitalized patients.

Oct 16, 2020

This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. Credit: CDC/Unsplash

Canadian COVID-19 trial gets additional $3.5 million in federal funding

The Canadian arm of a major international clinical trial—led by a University of British Columbia researcher—that aims to find the best treatment for COVID-19 has received an additional $3.5 million in funding from the federal government through the Canadian Institutes of Health Research (CIHR).

May 28, 2020